Skeletal muscle disorder
MONDO:0020120A disease involving the skeletal muscle tissue.
Also known as: disease of skeletal muscle tissue, disease or disorder of skeletal muscle tissue, disorder of skeletal muscle tissue, skeletal muscle tissue disease, skeletal muscle tissue disease or disorder
1366 clinical trials for this condition and its sub-types, 11 tagged with Skeletal muscle disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Skeletal muscle disorder
-
Myopathy 16 trials · 990 incl. sub-types
32 sub-types
- Myositis disease 105 trials · 298 incl. sub-types Sub-types →
- Muscular dystrophy 74 trials · 290 incl. sub-types Sub-types →
- Myofascial pain syndrome 157 trials · 228 incl. sub-types Sub-types →
- Muscular atrophy 97 trials Sub-types →
- Congenital myopathy 8 trials · 75 incl. sub-types Sub-types →
- Acute quadriplegic myopathy 14 trials
- Myopathy caused by variation in FKRP 0 trials · 8 incl. sub-types Sub-types →
- Hereditary inclusion-body myopathy 1 trial · 6 incl. sub-types Sub-types →
- Myopathy of extraocular muscle 1 trial · 5 incl. sub-types Sub-types →
- Drug-induced myopathy 2 trials Sub-types →
- Myopathy caused by variation in FKTN 1 trial · 2 incl. sub-types Sub-types →
- Collagen 6-related myopathy 1 trial Sub-types →
- Metabolic myopathy 1 trial Sub-types →
- Myopathy caused by variation in CRPPA 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in GMPPB 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMGNT1 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMT1 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMT2 0 trials · 1 incl. sub-types Sub-types →
- Myopathy due to myoadenylate deaminase deficiency 1 trial
- Polyglucosan body myopathy 0 trials · 1 incl. sub-types Sub-types →
- Rippling muscle disease 0 trials · 1 incl. sub-types Sub-types →
- Brody myopathy 0 trials
- FHL1-related myopathy 0 trials Sub-types →
- Hereditary continuous muscle fiber activity 0 trials
- Intermediate nemaline myopathy 0 trials Sub-types →
- Myopathy caused by variation in POMGNT2 0 trials Sub-types →
- Myopathy with abnormal lipid metabolism 0 trials
- Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 0 trials
- Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2 0 trials
- Myopathy, sarcoplasmic body 0 trials
- Proximal myopathy with extrapyramidal signs 0 trials
- Proximal myopathy with focal depletion of mitochondria 0 trials
-
Hereditary skeletal muscle disorder 1 trial · 406 incl. sub-types
33 sub-types
- Muscular dystrophy 74 trials · 290 incl. sub-types Sub-types →
- Congenital myopathy 8 trials · 75 incl. sub-types Sub-types →
- Congenital diaphragmatic hernia 45 trials Sub-types →
- Myopathy caused by variation in FKRP 0 trials · 8 incl. sub-types Sub-types →
- Hereditary inclusion-body myopathy 1 trial · 6 incl. sub-types Sub-types →
- Poland syndrome 2 trials
- Myopathy caused by variation in FKTN 1 trial · 2 incl. sub-types Sub-types →
- Inherited rippling muscle disease 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in CRPPA 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in GMPPB 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMGNT1 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMT1 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMT2 0 trials · 1 incl. sub-types Sub-types →
- Myopathy due to myoadenylate deaminase deficiency 1 trial
- Paramyotonia congenita of Von Eulenburg 1 trial
- Polyglucosan body myopathy 0 trials · 1 incl. sub-types Sub-types →
- ACTN2-related cardiac and skeletal myopathy 0 trials Sub-types →
- Brody myopathy 0 trials
- FHL1-related myopathy 0 trials Sub-types →
- Wieacker-Wolff syndrome (spectrum) 0 trials Sub-types →
- Hereditary continuous muscle fiber activity 0 trials
- Hereditary myopathy with lactic acidosis due to ISCU deficiency 0 trials
- Metabolic myopathy due to lactate transporter defect 0 trials
- Myopathy caused by variation in POMGNT2 0 trials Sub-types →
- Myopathy due to calsequestrin and SERCA1 protein overload 0 trials
- Myopathy with abnormal lipid metabolism 0 trials
- Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 0 trials
- Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2 0 trials
- Myopathy, sarcoplasmic body 0 trials
- Myosclerosis 0 trials
- Potassium-aggravated myotonia 0 trials Sub-types →
- Proximal myopathy with extrapyramidal signs 0 trials
- Proximal myopathy with focal depletion of mitochondria 0 trials
-
Rotator cuff syndrome 272 trials
-
Acquired skeletal muscle disease 0 trials · 166 incl. sub-types
5 sub-types
- Acquired idiopathic inflammatory myopathy 67 trials · 159 incl. sub-types Sub-types →
- Idiopathic camptocormia 7 trials
- Acquired rippling muscle disease 0 trials Sub-types →
- Idiopathic dropped head syndrome 0 trials
- Macrophagic myofasciitis 0 trials
-
Diaphragm disorder 27 trials · 91 incl. sub-types
5 sub-types
- Congenital diaphragmatic hernia 45 trials Sub-types →
- Respiratory paralysis 20 trials
- Diaphragmatic eventration 3 trials
- Diaphragmatic malformation 1 trial
- Diaphragmitis 0 trials
-
Myotonic syndrome 11 trials · 61 incl. sub-types
5 sub-types
- Myotonic dystrophy 56 trials · 57 incl. sub-types Sub-types →
- Nondystrophic myotonia 4 trials
- Laryngospasm, severe neonatal episodic 1 trial
- Paramyotonia congenita of Von Eulenburg 1 trial
- Potassium-aggravated myotonia 0 trials Sub-types →
-
Anismus 12 trials
-
Tel Hashomer camptodactyly syndrome 0 trials
-
Volkmann contracture 0 trials
-
Skeletal muscle neoplasm 0 trials
2 sub-types
- Benign skeletal muscle neoplasm 0 trials
- Skeletal muscle cancer 0 trials
Most studied deeper sub-types
-
Can an oral drug calm inflamed muscles in myositis?
Disease control Stopped earlyResearchers are testing an experimental oral drug called enpatoran in adults with dermatomyositis and polymyositis, two rare muscle-weakening diseases. Participants receive enpatoran or a placebo twice daily for up to 24 weeks while continuing their standard care. The trial measu…
Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could treating the neck ease shoulder pain?
Disease control Stopped earlyThis pilot study asks whether adding physical therapy for the neck to standard shoulder treatment can improve outcomes for people with shoulder impingement—a condition where shoulder tissue gets pinched, causing pain with overhead movements. Adults aged 40 to 70 with shoulder imp…
Sponsor: CAMC Health System • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control Stopped earlyThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase 1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Shoulder implant under review: will it last 10 years?
Disease control Stopped earlyThis study looked at a shoulder implant used to treat pain and joint problems from conditions like arthritis, fractures, and rotator cuff tears. It involved 67 adults who received the implant and tracked how long it lasted and any side effects over 10 years. The goal was to confi…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Shoulder surgery recovery: steroid trial halted after just 4 patients
Disease control Stopped earlyThis study tested whether taking the steroid oxandrolone for 12 weeks after rotator cuff repair could improve tendon healing and muscle mass. Only 4 people participated before the trial was stopped early. Because it was so small, we cannot draw any reliable conclusions about whet…
Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental pill aims to stop extra bone growth in rare disease
Disease control Stopped earlyThis phase 2 trial tested two doses of an oral drug called fidrisertib (IPN60130) in children and adults with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. The goal was to see if the drug could reduce new abnormal bone growth com…
Phase 2 • Sponsor: Clementia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
DMD drug tested in wheelchair users – but trial stops early
Disease control Stopped earlyThis study tested the safety of golodirsen (Vyondys 53) in boys and men with Duchenne muscular dystrophy who can no longer walk. Only 2 people took part before the trial was stopped early. Participants received weekly IV infusions for up to 96 weeks, with extra follow-up. The goa…
Phase 4 • Sponsor: Rare Disease Research, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug aims to tame hard-to-control seizures in rare mitochondrial disorders
Disease control Stopped earlyThis study tested a drug called vatiquinone in 68 people with mitochondrial disease and epilepsy that doesn't respond to standard treatments. Participants were randomly assigned to receive either vatiquinone or a placebo for 24 weeks to see if the drug could reduce the number of …
Phase 2/3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug OMS721 tested for rare kidney conditions
Disease control Stopped earlyThis study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results…
Phase 2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental CAR t therapy targets lupus and related diseases – but trial ends early
Disease control Stopped earlyThis early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the imm…
Early phase 1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene therapy for rare muscle disease shows early promise but study halted
Disease control Stopped earlyThis study tested a gene therapy called SRP-9003 for people with limb-girdle muscular dystrophy type 2E (LGMD2E), a rare genetic disease that causes muscle weakness. The treatment aimed to deliver a working gene to muscle cells to help them produce a missing protein. Only 6 peopl…
Phase 1/2 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control Stopped earlyThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental drug losmapimod tested in rare muscle disease – early hopes, but trial cut short
Disease control Stopped earlyThis study tested an experimental drug called losmapimod in 14 adults with FSHD1, a rare genetic condition that causes progressive muscle weakness. The main goal was to check safety and tolerability, and to see if the drug affects certain biological markers. The trial was termina…
Phase 2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug trial for duchenne MD halted early – what we know
Disease control Stopped earlyThis phase 2 study tested a drug called PGN-EDO51 in 7 people with Duchenne muscular dystrophy whose genetic mutation can be corrected by skipping exon 51. The drug was given by IV infusion to see if it is safe and tolerable. The trial was terminated, so results are limited.
Phase 2 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental gene therapy for DMD hits antibody barrier – study halted
Disease control Stopped earlyThis study tested a gene therapy (delandistrogene moxeparvovec) combined with a drug called imlifidase to see if it could safely deliver the therapy to boys with Duchenne muscular dystrophy who had antibodies that might block the treatment. Only 5 participants were planned, but t…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
FSHD drug trial halted midway: what happened?
Disease control Stopped earlyThis study tested a drug called losmapimod for people with a rare muscle-weakening disease called FSHD. The goal was to see if the drug could slow muscle loss and improve arm function over 48 weeks. About 260 adults with FSHD were randomly assigned to receive either losmapimod or…
Phase 3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Shoulder surgery tweak may help patients reach behind their backs
Disease control Stopped earlyThis study tested whether cutting a specific tendon (the conjoint tendon) during reverse shoulder replacement surgery helps patients move their hand behind their back better. The trial planned to enroll 26 adults having their first reverse shoulder replacement, but it was termina…
Sponsor: University of Missouri-Columbia • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental gene therapy targets duchenne MD in young boys
Disease control Stopped earlyThis Phase 2 trial tested a single dose of gene therapy (fordadistrogene movaparvovec) in 10 boys with early-stage Duchenne muscular dystrophy. The goal was to check safety and whether the therapy could help muscles produce a mini-dystrophin protein. The study was terminated earl…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Gene therapy for duchenne muscular dystrophy under Long-Term watch
Disease control Stopped earlyThis study follows 7 people with Duchenne muscular dystrophy who previously received an experimental gene therapy called fordadistrogene movaparvovec. Researchers will monitor them for 10 years to check for side effects and see if the treatment continues to help with movement. Th…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental drug losmapimod tested for rare muscle disease
Disease control Stopped earlyThis phase 2 trial tested the drug losmapimod in 76 adults with FSHD, a genetic condition that causes progressive muscle weakness. Participants took either losmapimod or a placebo for 48 weeks to see if the drug was safe and could help control the disease. The study was terminate…
Phase 2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Gene therapy trial for duchenne MD halted early – what we know
Disease control Stopped earlyThis early-stage trial tested a single infusion of gene therapy (PF-06939926) in 23 people with Duchenne muscular dystrophy, both those who could still walk and those who could not. The main goal was to check safety and tolerability, while also measuring dystrophin protein levels…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 17:12 UTC
-
Can plasma exchange clear the way for gene therapy in duchenne?
Disease control Stopped earlyThis early study tested whether a blood-cleaning procedure called plasmapheresis could allow boys with Duchenne muscular dystrophy who have antibodies against the gene therapy carrier to still receive the treatment. Only 3 boys were enrolled before the study was stopped early. Th…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
Experimental gene therapy for rare muscle disease tested in just 2 people
Disease control Stopped earlyThis was a very early (Phase 1) study testing a gene therapy called SRP-6004 for people with limb girdle muscular dystrophy type 2B/R2, a rare muscle-weakening disease. The goal was to see if a single IV infusion of the therapy is safe and can help the body produce a missing prot…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
Experimental gene therapy tested for rare muscular dystrophy
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SRP-9004 in just 4 people with limb girdle muscular dystrophy type 2D/R3, a rare muscle-weakening disease. The main goal was to check safety, not effectiveness. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:47 UTC
-
Lung disease drug tested in rare muscle condition – trial cut short
Disease control Stopped earlyThis study tested the drug nintedanib (Ofev) in 11 people with myositis-related interstitial lung disease, a condition where lung scarring occurs alongside muscle inflammation. The goal was to see if the drug is safe and tolerable when added to standard immune-suppressing treatme…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis Stopped earlyThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase 1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC
-
Pain patch put to the test for aching joints
Symptom relief Stopped earlyThis study tested a medicated patch containing ketoprofen (a pain reliever) for people with tendonitis or bursitis pain in the shoulder, elbow, or knee. About 381 adults with these conditions were randomly assigned to receive either the active patch or a placebo patch. The goal w…
Phase 3 • Sponsor: APR Applied Pharma Research s.a. • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Shoulder pain drug trial halted early
Symptom relief Stopped earlyThis study tested whether the drug secukinumab could reduce pain and improve function in adults with moderate to severe rotator cuff tendinopathy, a common shoulder condition. Participants received either the drug or a placebo for 24 weeks. The trial was terminated early, and res…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New rehab trick may boost knee recovery after meniscus repair
Symptom relief Stopped earlyThis study looked at whether adding blood flow restriction training to standard physical therapy helps people regain knee strength and muscle size after meniscus repair surgery. About 15 participants were split into two groups: one did standard rehab, the other added the special …
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Tiny wrist cyst surgery study ends early with only 3 patients
Symptom relief Stopped earlyThis study looked at whether cutting a small nerve in the wrist during surgery to remove a ganglion cyst helps reduce pain and improve hand function more than just removing the cyst alone. Only 3 adults with painful wrist cysts took part before the study was stopped early. The re…
Sponsor: Kenneth Taylor, M.D. • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
New drug aimed at shoulder pain fails to complete trial
Symptom relief Stopped earlyThis study tested the drug secukinumab against a placebo in 60 adults with moderate to severe rotator cuff tendinopathy, a painful shoulder condition. The goal was to see if secukinumab could improve symptoms and shoulder function over 24 weeks. However, the trial was terminated …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Tiny study on blood flow cuffs for shoulder injuries ends early
Symptom relief Stopped earlyThis study tested whether using a blood flow restriction (BFR) cuff during physical therapy could help people with shoulder injuries regain strength and return to activity faster. Only 3 people took part before the study was stopped early. The approach uses a special tourniquet t…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Gut hormone shot aims to strengthen fragile bones in kids with muscle diseases
Knowledge-focused Stopped earlyThis study tested whether two gut hormones, GIP and GLP-2, could reduce bone breakdown in children with spinal muscular atrophy, cerebral palsy, or Duchenne muscular dystrophy who use wheelchairs. Participants received a liquid meal and then either a hormone injection or a placeb…
Sponsor: University of Copenhagen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Muscle stem cell study ends early — but may pave way for future treatments
Knowledge-focused Stopped earlyThis study looked at whether muscle stem cells (mesoangioblasts) from people with muscle loss due to cancer or aging are healthy enough to be used for future cell therapy. Researchers took small muscle samples and blood from 7 participants and measured how well the cells grew and…
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Shoulder surgery showdown: onlay vs. inlay – which works better?
Knowledge-focused Stopped earlyThis study looked at two different ways surgeons place the top part of a reverse shoulder replacement: sitting on top of the bone (onlay) or set into the bone (inlay). The goal was to see if one method leads to better arm movement after surgery. The study enrolled 19 people with …
Sponsor: Corewell Health East • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Which rehab works best after shoulder surgery? study aims to find out.
Knowledge-focused Stopped earlyThis study compared three different rehabilitation programs after arthroscopic rotator cuff repair. Participants were divided into groups with varying periods of immobilization and passive motion before starting active rehab. The goal was to see which program leads to the best sh…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
One-Person study aims to unlock FSHD mysteries
Knowledge-focused Stopped earlyThis study looked at one person with facioscapulohumeral muscular dystrophy (FSHD) to better understand the disease. Researchers examined muscle tissue and checked for specific biomarkers. The goal was to learn more about how FSHD affects the body, not to test a treatment.
Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:43 UTC